Scroll

vincristine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
vinca alkaloids	2825	57-22-7

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: vincristine (+)-Vincristine leucristine vincristin vinkristin 22-oxo-vincaleukoblastine vincristine sulfate oncovin	An antitumor alkaloid isolated from VINCA ROSEA. (Merck, 11th ed.) Molecular weight: 824.97 Formula: C46H56N4O10 CLOGP: 3.07 LIPINSKI: 2 HAC: 14 HDO: 3 TPSA: 171.17 ALOGS: -4.44 ROTB: 10 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

vincristine
(+)-Vincristine
leucristine
vincristin
vinkristin
22-oxo-vincaleukoblastine
vincristine sulfate
oncovin

An antitumor alkaloid isolated from VINCA ROSEA. (Merck, 11th ed.)

Molecular weight: 824.97
Formula: C46H56N4O10
CLOGP: 3.07
LIPINSKI: 2
HAC: 14
HDO: 3
TPSA: 171.17
ALOGS: -4.44
ROTB: 10

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

Show entries

Search:

Property	Value	Reference
t_half (Half-life)	23 hours	Lombardo F, Berellini G, Obach RS
Vd (Volume of distribution)	2.40 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	2 mL/min/kg	Lombardo F, Berellini G, Obach RS
EoM (Fraction excreted unchanged in urine)	15 %	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	10 mg/mL	Benet LZ, Broccatelli F, Oprea TI
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
fu (Fraction unbound in plasma)	0.40 %	Lombardo F, Berellini G, Obach RS

Showing 1 to 7 of 7 entries

Previous1Next

Approvals:

Date	Agency	Company	Orphan
July 10, 1963	FDA

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Febrile neutropenia	4816.95	15.32	2412	66778	116037	63303795
Neutropenia	1580.12	15.32	1394	67796	173611	63246221
Disease progression	1130.60	15.32	990	68200	121768	63298064
Febrile bone marrow aplasia	869.82	15.32	320	68870	7005	63412827
Haematotoxicity	820.74	15.32	328	68862	9048	63410784
Pancytopenia	793.47	15.32	732	68458	96201	63323631
Diffuse large B-cell lymphoma recurrent	752.02	15.32	217	68973	2103	63417729
Product use in unapproved indication	643.94	15.32	880	68310	178200	63241632
Bone marrow failure	606.48	15.32	385	68805	28905	63390927
Thrombocytopenia	586.35	15.32	771	68419	150386	63269446

Showing 1 to 10 of 615 entries

Previous1 2 3 4 5…62Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Febrile neutropenia	4731.07	14.12	3441	88755	133408	34731327
Neutropenia	1399.99	14.12	1885	90311	154893	34709842
Disease progression	1105.65	14.12	1391	90805	106686	34758049
Myelosuppression	774.21	14.12	534	91662	18731	34846004
Diffuse large B-cell lymphoma recurrent	686.08	14.12	274	91922	2954	34861781
Product use in unapproved indication	673.05	14.12	1151	91045	116348	34748387
Mucosal inflammation	650.75	14.12	646	91550	37976	34826759
Haematotoxicity	602.61	14.12	334	91862	7860	34856875
Second primary malignancy	578.72	14.12	321	91875	7565	34857170
Hepatitis B reactivation	565.22	14.12	252	91944	3639	34861096

Showing 1 to 10 of 640 entries

Previous1 2 3 4 5…64Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Febrile neutropenia	9056.15	13.08	5463	139673	225536	79373716
Neutropenia	2735.95	13.08	2974	142162	284736	79314516
Disease progression	1516.16	13.08	1770	143366	182592	79416660
Haematotoxicity	1327.61	13.08	621	144515	14898	79584354
Product use in unapproved indication	1245.76	13.08	1879	143257	248480	79350772
Pancytopenia	1218.97	13.08	1504	143632	164241	79435011
Mucosal inflammation	1141.79	13.08	1009	144127	74571	79524681
Myelosuppression	1136.77	13.08	779	144357	39517	79559735
Second primary malignancy	1065.40	13.08	521	144615	13829	79585423
Bone marrow failure	1048.71	13.08	815	144321	50292	79548960

Showing 1 to 10 of 1,005 entries

Previous1 2 3 4 5…101Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	L01CA02	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS Vinca alkaloids and analogues
CHEBI has role	CHEBI:23888	drugs
CHEBI has role	CHEBI:35610	antineoplastic agents
CHEBI has role	CHEBI:60832	tubulin modulators
CHEBI has role	CHEBI:61951	microtubule destabilizing role
CHEBI has role	CHEBI:76924	plant metabolites
CHEBI has role	CHEBI:176497	geroprotectors
FDA CS	M0022674	Vinca Alkaloids
FDA EPC	N0000175612	Vinca Alkaloid
MeSH PA	D050256	Antimitotic Agents

Showing 1 to 10 of 13 entries

Previous1 2Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID	DOID
Acute lymphoid leukemia	indication	91857003	DOID:9952
Diffuse non-Hodgkin's lymphoma, large cell	indication	109969005
Hodgkin's disease	indication	118599009
Non-Hodgkin's lymphoma	indication	118601006
Burkitt's lymphoma	indication	118617000
Rhabdomyosarcoma	indication	302847003	DOID:3247
Nephroblastoma	indication	302849000	DOID:2154
Follicular non-Hodgkin's lymphoma	indication	308121000
Neuroblastoma	indication	432328008	DOID:769
Astrocytoma, anaplastic	off-label use	55353007	DOID:3078

Showing 1 to 10 of 36 entries

Previous1 2 3 4Next

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Show entries

Search:

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	10.02	acidic
pKa2	13.81	acidic
pKa3	7.2	Basic
pKa4	6.58	Basic

Showing 1 to 4 of 4 entries

Previous1Next

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Show entries

Search:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Tubulin beta	Tumour-associated antigen	P07437 Q9H4B7 Q13885 Q9BVA1 Q13509 P04350 P68371 Q9BUF5 Q3ZCM7	TBB5_HUMAN TBB1_HUMAN TBB2A_HUMAN TBB2B_HUMAN TBB3_HUMAN TBB4A_HUMAN TBB4B_HUMAN TBB6_HUMAN TBB8_HUMAN	INHIBITOR			SCIENTIFIC LITERATURE	SCIENTIFIC LITERATURE
Multidrug resistance protein 1	Transporter	P08183	MDR1_HUMAN				WOMBAT-PK
Canalicular multispecific organic anion transporter 1	Transporter	Q92887	MRP2_HUMAN				WOMBAT-PK
Multidrug resistance-associated protein 1	Transporter	P33527	MRP1_HUMAN				WOMBAT-PK
Multidrug resistance-associated protein 7	Transporter	Q5T3U5	MRP7_HUMAN				WOMBAT-PK
Tubulin	Structural		TBB2B_BOVIN Q862F3_BOVIN Q862L2_BOVIN		IC50	5.74	CHEMBL

Showing 1 to 6 of 6 entries

Previous1Next

External reference:

Show entries

Search:

ID	Source
R1Q	PDB_CHEM_ID
002656	NDDF
004894	NDDF
11202	RXNORM
1440	INN_ID
2068-78-2	SECONDARY_CAS_RN
23079006	SNOMEDCT_US
387126006	SNOMEDCT_US
387427007	SNOMEDCT_US
4017542	VANDF

Showing 1 to 10 of 28 entries

Previous1 2 3Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Vincasar PFS	HUMAN PRESCRIPTION DRUG LABEL	1	0703-4402	INJECTION, SOLUTION	1 mg	INTRAVENOUS	ANDA	20 sections
Vincasar PFS	HUMAN PRESCRIPTION DRUG LABEL	1	0703-4412	INJECTION, SOLUTION	1 mg	INTRAVENOUS	ANDA	20 sections
VinCRIStine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	1	61703-309	INJECTION, SOLUTION	1 mg	INTRAVENOUS	ANDA	22 sections
VinCRIStine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	1	61703-309	INJECTION, SOLUTION	1 mg	INTRAVENOUS	ANDA	22 sections
VinCRIStine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	1	61703-309	INJECTION, SOLUTION	1 mg	INTRAVENOUS	ANDA	22 sections
VinCRIStine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	1	61703-309	INJECTION, SOLUTION	1 mg	INTRAVENOUS	ANDA	22 sections
VinCRIStine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	1	61703-309	INJECTION, SOLUTION	1 mg	INTRAVENOUS	ANDA	22 sections
VinCRIStine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	1	61703-309	INJECTION, SOLUTION	1 mg	INTRAVENOUS	ANDA	22 sections

Showing 1 to 8 of 8 entries

Previous1Next